Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 5/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL550819 | 1.00 | HTR7 (0.42) | HTR7HCRTR2DPP4KDM1AKDM4E | |
| SCHEMBL17082030 | 1.00 | HTR7 (0.42) | HTR7HCRTR2DPP4KDM1AKDM4E | |
| SCHEMBL17082026 | 0.88 | HSD11B1 (0.46) | HTR7HCRTR2DPP4KDM4EABL1 | |
| SCHEMBL550693 | 0.88 | HSD11B1 (0.46) | HTR7HCRTR2DPP4KDM4EABL1 | |
| SCHEMBL550443 | 0.86 | HSD11B1 (0.41) | HTR7HCRTR2HSD11B1 | |
| SCHEMBL17082140 | 0.86 | HSD11B1 (0.41) | HTR7HCRTR2HSD11B1 | |
| SCHEMBL550444 | 0.86 | HSD11B1 (0.41) | HTR7HCRTR2HSD11B1 | |
| SCHEMBL549186 | 0.86 | KDM4E (0.45) | HTR7HCRTR2DPP4KDM4EABL1 | |
| SCHEMBL549372 | 0.86 | KDM4E (0.45) | HTR7HCRTR2DPP4KDM4EABL1 | |
| SCHEMBL549187 | 0.86 | KDM4E (0.45) | HTR7HCRTR2DPP4KDM4EABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563570-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | claimed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | claimed |
| EP-2450351-A1 | Lactam compounds and their use as pharmaceuticals | Incyte Corporation (US) | 2012-05-09 | — | — | EP | claimed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | claimed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | claimed |
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-01 | — | — | US | claimed |
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | disclosed |
| US-8563570-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2450351-A1 | Lactam compounds and their use as pharmaceuticals | Incyte Corporation (US) | 2012-05-09 | — | — | EP | disclosed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | HSD11B1, HSD11B2, HSD17B1 | HTR7 3714/4885HCRTR2 3116/4885DPP4 1228/4885 |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | HTR7 3714/4885HCRTR2 3116/4885DPP4 1228/4885 |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | HTR7 3714/4885HCRTR2 3116/4885DPP4 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.